drugset / Trial / NCT00465959
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
Phase 1/2
Completed
24 enrolled
Endo USA Inc., a Keenova Therapeutics Company
Alkermes, Inc. · collab
RandomizedCrossoverDouble-blindTreatment
Summary
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
Timeline
- Start
- 2007-04
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trospium | Small molecule | 400 mg | Inhaled |
| Subject | Trospium | Small molecule | 800 mg | Inhaled |